Comparing X-3 To N2vac Polyethylene With the Triathlon Total Knee System

This study has been withdrawn prior to enrollment.
(Not funded at this time.)
Sponsor:
Collaborator:
Stryker Canada LP
Information provided by:
Dalhousie University
ClinicalTrials.gov Identifier:
NCT00665964
First received: April 22, 2008
Last updated: August 10, 2009
Last verified: August 2009

April 22, 2008
August 10, 2009
May 2008
May 2020   (final data collection date for primary outcome measure)
survival rate of polyethylene [ Time Frame: 10 years ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00665964 on ClinicalTrials.gov Archive Site
  • pain [ Time Frame: 10 years ] [ Designated as safety issue: No ]
  • function [ Time Frame: 10 years ] [ Designated as safety issue: No ]
  • radiographic outcomes [ Time Frame: 10 years ] [ Designated as safety issue: No ]
  • health related quality of life [ Time Frame: 10 years ] [ Designated as safety issue: No ]
  • adverse events [ Time Frame: 10 years ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Comparing X-3 To N2vac Polyethylene With the Triathlon Total Knee System
A Prospective, Randomized, Multi-center Study Comparing the Ten-Year Survival for X-3 Polyethylene to N2vac Polyethylene When Used With the Triathlon Posterior Stabilized (PS) Total Knee System

Methodology: This study will be a randomized, multi-center evaluation comparing N2vac polyethylene inserts and patellas with X3 inserts and patellas when used in the Triathlon PS total knee system.

Study Duration: 12-18 month enrollment period + 10 year follow-up for each case years total duration

Multi-centre study

Objectives

Primary: To compare the 10 year implant survival of the Triathlon PS total knee system when X3 polyethylene components are used to the same knee system when N2Vac components are used.

Secondary: To compare pain, function, radiographic outcomes, and health related quality of life of subjects in both treatment groups. Safety will be assessed by comparison of adverse events between the groups.

Number of Subjects 384 cases (197 each group)

Not Provided
Interventional
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Osteoarthritis
  • Device: X-3 polyethylene
    highly cross-linked polyethylene for knee arthroplasty
  • Device: N2Vac polethylene
    conventional polyethylene
  • Experimental: X-3
    X-3 polyethylene which is a new highly cross-linked poly that is theorized to be more durable in vivo
    Intervention: Device: X-3 polyethylene
  • Active Comparator: N2Vac polethylene
    conventional polyethylene
    Intervention: Device: N2Vac polethylene
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
384
May 2020
May 2020   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • The subject requires a primary cemented total knee replacement.
  • The subject has a diagnosis of osteoarthritis (OA), traumatic arthritis (TA), or avascular necrosis (AVN).
  • The subject has intact collateral ligaments.
  • The subject has signed the ethic committee approved, study specific Informed Patient Consent Form.
  • The subject is willing and able to comply with post-operative scheduled clinical and radiographic evaluations and rehabilitation.

Exclusion Criteria:

  • The subject has inflammatory arthritis.
  • The subject is morbidly obese, BMI > 40.
  • The subject has a history of total or unicompartmental reconstruction of the affected joint.
  • The subject has had a high tibial osteotomy or femoral osteotomy.
  • The subject has a neuromuscular or neurosensory deficiency, that would limit the ability to assess the performance of the device.
  • The subject has a systemic or metabolic disorder leading to progressive bone deterioration.
  • The subject is immunologically suppressed, or receiving chronic steroids (>30 days duration).
  • The subject's bone stock is compromised by disease or infection and cannot provide adequate support and/or fixation to the prosthesis.
  • The subject has had a knee fusion at the affected joint.
  • The subject has an active or suspected latent infection in or about the knee joint.
  • The subject is a prisoner.
Both
21 Years to 75 Years
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT00665964
CDHA-RS/2007-249
No
Michael J. Dunbar, Division of Orthopaedics, Dalhousie University
Dalhousie University
Stryker Canada LP
Principal Investigator: Michael J. Dunbar Dalhousie University
Dalhousie University
August 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP